FOLH1 and neoplasm: Dual radionuclide approaches, such as Ac-225/Lu-177 PSMA combination therapy, have been explored for their synergistic effects in overcoming heterogeneous tumor resistance, potentially leading to improved therapeutic outcomes [16].